- BioPure’s new site will increase provision of vital fluid components to the biopharmaceutical industry
- The facility is five times the size of BioPure’s previous location
- Product consistency and quality ensured via revalidation of each machine
Biopharmaceutical fluid path component provider, BioPure, part of Watson-Marlow Fluid Technology Group (WMFTG), receives the keys for its custom-built facility at Dunsbury Park, with production due to begin in March 2022. Beginning construction in 2019, the new facility is five times the size of the company’s previous two buildings combined and will provide much needed additional capacity to support the company’s ongoing growth and provide the best service to its customers.
BioPure has pioneered the design, development, and delivery of innovative engineering solutions for customers in the global biotechnology and pharmaceutical industries since 1998. The Company became part of WMFTG in 2014 and has experienced rapid growth, and this is set to continue over the next five years.
Comprising 120,000 sq. ft, this new facility will help to support BioPure’s ambitious vision, growth and commitment to supporting customers worldwide. The company’s key aims include simplifying production operations, lowering cGMP manufacturing costs and reducing process validation. The new facility, based just 4 miles from the current site in Portsmouth, is now home to BioPure’s current team of 232 employees and aims to bring on a diverse range of new talent in manufacturing, engineering, production, design, assembly, logistics and administration. The expansion will create 130 new jobs across a range of disciplines and the company is looking for talented individuals to join the team.
To ensure customers receive products and services of the highest quality, the company will continue to use existing production equipment at the new site. There will be no change in raw material, nor will there be any change in processing equipment or process methods. Revalidation of each moulding machine and metrology comparison with products from the old manufacturing process has ensured that there is no change to the fit, form or function of BioPure’s products.
Steve Feasey, Manager Director of BioPure, commented, “This is a very exciting time for BioPure, with demand for our products increasing year on year. We’re thrilled to get the keys to our new facility, providing increased capacity for us to deliver our high-quality fluid path components and strengthen our support for the pharmaceutical and biotechnology industry. This demonstrates our ongoing commitment to improving our customer service and our team are excited to start work from this state-of-the-art facility. We look forward to continuing to grow and develop more market-leading fluid management solutions.”